FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3141555379> ?p ?o ?g. }

• W3141555379 endingPage "60" @default.
• W3141555379 startingPage "54" @default.
• W3141555379 abstract "The hypolipidemic therapy is one of the essential components for the management of patients with cardiovascular diseases (CVD). In this regard, the main task of modern research is to find new targets for creating additional effective groups of lipid-lowering drugs. In 2003, a Canadian and French research team led by N. Seidah and M. Abifadel discovered a new enzyme, proprotein convertase subtilisin-kexin type 9 (PCSK9), which plays an important role in lipid metabolism.&#x0D; The main mechanism of action of PCSK9 is to regulate the density of low-density lipoprotein receptors (LDLR) in the cell membrane of hepatocytes. The increased activity of PCSK9 significantly accelerates the degradation of LDLR and leads to an increase in the concentration of atherogenic classes of lipoproteins the low-density lipoproteins (LDL). A reduced activity of PCSK9, on the contrary, is accompanied by a decrease in the concentration of LDL and a decrease in the risk of developing atherosclerosis and CVD. The second, recently discovered and less studied, mechanism of the protearogenic action of PCSK9 is the enhancement of inflammatory processes in the atherosclerotic plaque. Given this unfavorable contribution of PCSK9 to the development and progression of atherosclerosis and CVD, the main task of the researchers was to develop drugs that inhibit this enzyme. To date, several new drug groups have been developed that target the biosynthesis steps and the function of PCSK9.&#x0D; In this article, we will focus in detail on the discussion of the mechanisms of action and effectiveness of the following groups of lipid-lowering drugs: anti-PCSK9 monoclonal antibodies (alirocumab, evolocumab), small interfering ribonucleic acids (incliciran) and antisense nucleotides." @default.
• W3141555379 created "2021-04-13" @default.
• W3141555379 creator A5036553348 @default.
• W3141555379 creator A5048448754 @default.
• W3141555379 creator A5053057996 @default.
• W3141555379 creator A5056638295 @default.
• W3141555379 creator A5059294927 @default.
• W3141555379 creator A5063065134 @default.
• W3141555379 date "2021-03-29" @default.
• W3141555379 modified "2023-09-27" @default.
• W3141555379 title "New groups of hypolipidemic drugs based on inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9). Part 1" @default.
• W3141555379 cites W1647075334 @default.
• W3141555379 cites W1870321215 @default.
• W3141555379 cites W1898803325 @default.
• W3141555379 cites W1971198704 @default.
• W3141555379 cites W1976691226 @default.
• W3141555379 cites W1979685378 @default.
• W3141555379 cites W2001314633 @default.
• W3141555379 cites W2001328643 @default.
• W3141555379 cites W2006588520 @default.
• W3141555379 cites W2040612932 @default.
• W3141555379 cites W2046181127 @default.
• W3141555379 cites W2046707901 @default.
• W3141555379 cites W2054610237 @default.
• W3141555379 cites W2067539811 @default.
• W3141555379 cites W2076431356 @default.
• W3141555379 cites W2078669364 @default.
• W3141555379 cites W2078890343 @default.
• W3141555379 cites W2088358411 @default.
• W3141555379 cites W2093667080 @default.
• W3141555379 cites W2100932663 @default.
• W3141555379 cites W2130886644 @default.
• W3141555379 cites W2136034547 @default.
• W3141555379 cites W2144861484 @default.
• W3141555379 cites W2146769790 @default.
• W3141555379 cites W2155598961 @default.
• W3141555379 cites W2286637366 @default.
• W3141555379 cites W2570432860 @default.
• W3141555379 cites W2595169180 @default.
• W3141555379 cites W2596179513 @default.
• W3141555379 cites W2622520030 @default.
• W3141555379 cites W2625181578 @default.
• W3141555379 cites W2800649167 @default.
• W3141555379 cites W2803843543 @default.
• W3141555379 cites W2899997727 @default.
• W3141555379 cites W2948814534 @default.
• W3141555379 cites W2995227437 @default.
• W3141555379 cites W2996335591 @default.
• W3141555379 cites W3086371537 @default.
• W3141555379 cites W3088344876 @default.
• W3141555379 cites W4238580056 @default.
• W3141555379 cites W4240735590 @default.
• W3141555379 cites W4255471044 @default.
• W3141555379 doi "https://doi.org/10.35693/2500-1388-2021-6-1-54-60" @default.
• W3141555379 hasPublicationYear "2021" @default.
• W3141555379 type Work @default.
• W3141555379 sameAs 3141555379 @default.
• W3141555379 citedByCount "0" @default.
• W3141555379 crossrefType "journal-article" @default.
• W3141555379 hasAuthorship W3141555379A5036553348 @default.
• W3141555379 hasAuthorship W3141555379A5048448754 @default.
• W3141555379 hasAuthorship W3141555379A5053057996 @default.
• W3141555379 hasAuthorship W3141555379A5056638295 @default.
• W3141555379 hasAuthorship W3141555379A5059294927 @default.
• W3141555379 hasAuthorship W3141555379A5063065134 @default.
• W3141555379 hasBestOaLocation W31415553791 @default.
• W3141555379 hasConcept C170493617 @default.
• W3141555379 hasConcept C181199279 @default.
• W3141555379 hasConcept C185592680 @default.
• W3141555379 hasConcept C202751555 @default.
• W3141555379 hasConcept C2776120743 @default.
• W3141555379 hasConcept C2778163477 @default.
• W3141555379 hasConcept C2778824825 @default.
• W3141555379 hasConcept C2778849439 @default.
• W3141555379 hasConcept C2779811187 @default.
• W3141555379 hasConcept C2780072125 @default.
• W3141555379 hasConcept C2780948078 @default.
• W3141555379 hasConcept C43554185 @default.
• W3141555379 hasConcept C55493867 @default.
• W3141555379 hasConcept C71924100 @default.
• W3141555379 hasConcept C98274493 @default.
• W3141555379 hasConceptScore W3141555379C170493617 @default.
• W3141555379 hasConceptScore W3141555379C181199279 @default.
• W3141555379 hasConceptScore W3141555379C185592680 @default.
• W3141555379 hasConceptScore W3141555379C202751555 @default.
• W3141555379 hasConceptScore W3141555379C2776120743 @default.
• W3141555379 hasConceptScore W3141555379C2778163477 @default.
• W3141555379 hasConceptScore W3141555379C2778824825 @default.
• W3141555379 hasConceptScore W3141555379C2778849439 @default.
• W3141555379 hasConceptScore W3141555379C2779811187 @default.
• W3141555379 hasConceptScore W3141555379C2780072125 @default.
• W3141555379 hasConceptScore W3141555379C2780948078 @default.
• W3141555379 hasConceptScore W3141555379C43554185 @default.
• W3141555379 hasConceptScore W3141555379C55493867 @default.
• W3141555379 hasConceptScore W3141555379C71924100 @default.
• W3141555379 hasConceptScore W3141555379C98274493 @default.
• W3141555379 hasIssue "1" @default.
• W3141555379 hasLocation W31415553791 @default.

• next